BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Compare BAYER ARTHRITIS PAIN REGIMEN, EXT STR  to:
Compare
Compare

Generic Name for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Aspirin 500mg; e-c caplets.

Legal Classification:

OTC

Pharmacological Class for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Salicylate.

Manufacturer of BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Bayer Corp, Consumer Care Div.

Indications for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Arthritic and rheumatic conditions.

Adult dose for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Rheumatoid arthritis, arthritis and pleurisy of SLE: initially 3g daily in divided doses; target plasma salicylate level 150–300micrograms/mL. Osteoarthritis: up to 3g/day in divided doses. Spondyloarthropathies: up to 4g/day in divided doses.

Children's dosing for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

JRA: initially 90–130mg/kg per day in divided doses; target plasma salicylate level 150–300micrograms/mL.

Also:

Contraindications for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

NSAID allergy. Viral infection in children and teenagers. 3rd trimester pregnancy.

Precautions for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy, nursing mothers: not recommended.

Interactions for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction.

Adverse Reactions for BAYER ARTHRITIS PAIN REGIMEN, EXT STR

GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism.

How is BAYER ARTHRITIS PAIN REGIMEN, EXT STR supplied?

Ext Str Arthritis Reg—50
Ext Str tabs, caplets, Plus—50
Ext Str gelcaps—40, 80
Bayer Tabs—12, 24, 50, 100, 200, 300, 365
Caplets—50, 100, 200

Related Disease:

Arthritis~NSAIDs
Juvenile rheumatoid arthritis
Rheumatoid arthritis

Related Resources

Xiaflex available for Dupuytren's contracture

March 08, 2010

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Xiaflex approved for Dupuytren's contracture

February 03, 2010

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of SBI-087 for treatment of rheumatoid arthritis (RA)

January 11, 2010

Trubion Pharmaceuticals announced the initiation of a Phase 2 trial of SBI-087 for the treatment of rheumatoid arthritis (RA).

Actemra approved for moderately to severely active rheumatoid arthritis

January 11, 2010

The FDA has approved Actemra (tocilizumab, from Roche) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.